99 related articles for article (PubMed ID: 24341950)
1. Synthesis, characterization and in vitro extracellular and intracellular activity against Mycobacterium tuberculosis infection of new second-line antitubercular drug-palladium complexes.
Giovagnoli S; Marenzoni ML; Nocchetti M; Santi C; Blasi P; Schoubben A; Ricci M
J Pharm Pharmacol; 2014 Jan; 66(1):106-21. PubMed ID: 24341950
[TBL] [Abstract][Full Text] [Related]
2. [The rates of resistance to second-line drugs in multidrug resistant Mycobacterium tuberculosis strains].
Kayali R; Cöplü N; Ceyhan I; Ocak F; Citil BE; Esen B
Mikrobiyol Bul; 2006; 40(1-2):1-7. PubMed ID: 16775950
[TBL] [Abstract][Full Text] [Related]
3. Pre-XDR & XDR in MDR and Ofloxacin and Kanamycin resistance in non-MDR Mycobacterium tuberculosis isolates.
Jain A; Dixit P; Prasad R
Tuberculosis (Edinb); 2012 Sep; 92(5):404-6. PubMed ID: 22789499
[TBL] [Abstract][Full Text] [Related]
4. Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs.
Toungoussova OS; Mariandyshev AO; Bjune G; Caugant DA; Sandven P
Eur J Clin Microbiol Infect Dis; 2005 Mar; 24(3):202-6. PubMed ID: 15742171
[TBL] [Abstract][Full Text] [Related]
5. Straightforward palladium-mediated synthesis and biological evaluation of benzo[j]phenanthridine-7,12-diones as anti-tuberculosis agents.
Cappoen D; Jacobs J; Nguyen Van T; Claessens S; Diels G; Anthonissen R; Einarsdottir T; Fauville M; Verschaeve L; Huygen K; De Kimpe N
Eur J Med Chem; 2012 Feb; 48():57-68. PubMed ID: 22182928
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of kanamycin, viomycin and capreomycin resistance of Mycobacterium tuberculosis].
Tomoda T; Minami Y; Maekawa Y; Oi Y
Rinsho Byori; 1971 Jun; 19(6):423-6. PubMed ID: 4111341
[No Abstract] [Full Text] [Related]
7. Evaluation of BACTEC MGIT 960 system for the second-line drugs susceptibility testing of Mycobacterium tuberculosis in China.
Zhao LL; Xia Q; Lin N; Liu B; Zhao XQ; Liu Z; Wan KL
J Microbiol Methods; 2012 Oct; 91(1):212-4. PubMed ID: 22766324
[TBL] [Abstract][Full Text] [Related]
8. First proficiency testing of second-line anti-tuberculosis drug susceptibility testing in 12 provinces of China.
Jiang GL; Chen X; Song Y; Zhao Y; Huang H; Kam KM
Int J Tuberc Lung Dis; 2013 Nov; 17(11):1491-4. PubMed ID: 24125456
[TBL] [Abstract][Full Text] [Related]
9. Thin-layer agar for detection of resistance to rifampicin, ofloxacin and kanamycin in Mycobacterium tuberculosis isolates.
Martin A; Paasch F; Von Groll A; Fissette K; Almeida P; Varaine F; Portaels F; Palomino JC
Int J Tuberc Lung Dis; 2009 Oct; 13(10):1301-4. PubMed ID: 19793437
[TBL] [Abstract][Full Text] [Related]
10. Assessment of trends of ofloxacin resistance in Mycobacterium tuberculosis.
Verma JS; Nair D; Rawat D; Manzoor N
Indian J Med Microbiol; 2011; 29(3):280-2. PubMed ID: 21860110
[TBL] [Abstract][Full Text] [Related]
11. Rapid detection of Mycobacterium tuberculosis resistance to second-line drugs by use of the manual mycobacterium growth indicator tube system.
Martin A; von Groll A; Fissette K; Palomino JC; Varaine F; Portaels F
J Clin Microbiol; 2008 Dec; 46(12):3952-6. PubMed ID: 18945838
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and antitubercular activity of palladium and platinum complexes with fluoroquinolones.
Vieira LM; de Almeida MV; Lourenço MC; Bezerra FA; Fontes AP
Eur J Med Chem; 2009 Oct; 44(10):4107-11. PubMed ID: 19482387
[TBL] [Abstract][Full Text] [Related]
13. Activity of phosphino palladium(II) and platinum(II) complexes against HIV-1 and Mycobacterium tuberculosis.
Gama NH; Elkhadir AY; Gordhan BG; Kana BD; Darkwa J; Meyer D
Biometals; 2016 Aug; 29(4):637-50. PubMed ID: 27246555
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and structure-activity relationship studies of tryptanthrins as antitubercular agents.
Hwang JM; Oh T; Kaneko T; Upton AM; Franzblau SG; Ma Z; Cho SN; Kim P
J Nat Prod; 2013 Mar; 76(3):354-67. PubMed ID: 23360475
[TBL] [Abstract][Full Text] [Related]
15. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
16. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein.
Hartkoorn RC; Chandler B; Owen A; Ward SA; Bertel Squire S; Back DJ; Khoo SH
Tuberculosis (Edinb); 2007 May; 87(3):248-55. PubMed ID: 17258938
[TBL] [Abstract][Full Text] [Related]
17. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System.
Rodrigues C; Jani J; Shenai S; Thakkar P; Siddiqi S; Mehta A
Int J Tuberc Lung Dis; 2008 Dec; 12(12):1449-55. PubMed ID: 19017456
[TBL] [Abstract][Full Text] [Related]
18. Multicenter research on the BACTEC MGIT 960 system for the second-line drugs susceptibility testing of Mycobacterium tuberculosis in China.
Zhao LL; Liang YP; Huang MX; Tan YH; Jiang Y; Chen Y; Liu Z; Gao M; Wei S; Chen Z; Wu J; Jiang Y; Wan KL
Diagn Microbiol Infect Dis; 2013 Dec; 77(4):330-4. PubMed ID: 24091105
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the GenoType® MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs.
Said HM; Kock MM; Ismail NA; Baba K; Omar SV; Osman AG; Hoosen AA; Ehlers MM
Int J Tuberc Lung Dis; 2012 Jan; 16(1):104-9. PubMed ID: 22236854
[TBL] [Abstract][Full Text] [Related]
20. Low levels of second-line drug resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Rwanda.
Umubyeyi A; Rigouts L; Shamputa IC; Dediste A; Struelens M; Portaels F
Int J Infect Dis; 2008 Mar; 12(2):152-6. PubMed ID: 17950021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
